Marja-Liisa Sumelahti, MD, PhD, Specialist in Neurology, Faculty of Medicine and Health Technology, Tampere University, Finland. 
There has been concern during the Covid pandemic that the immunosuppressive effects of medicines may increase the risk of infection. Little is known about the effect of migraine preventive medication on immune function but laboratory evidence of immunosuppression has not been reflected in clinical practice. Despite theoretical concerns, CGRP antagonists may confer some degree of protection against the complications of Covid.

References

1. Sumelahti ML, Sumanen M, Sumanen MS, et al. My Migraine Voice survey: disease impact on healthcare resource utilization, personal and working life in Finland. J Headache Pain. 2020;21:118. doi: 10.1186/ s10194-020-01185-4.
2. Zaccara G, Giovannelli F, Giorgi FS, et al. Do antiepileptic drugs increase the risk of infectious diseases? A meta-analysis of placebo-controlled studies. Br J Clin Pharmacol. 2017;83:1873-1879.
3. Maier IL, Karch A, Mikolajczyk R, et al. Effect of betablocker therapy on the risk of infections and death after acute stroke—a historical cohort study. PLoS One. 2015 Feb 2;10(2):e0116836. doi: 10.1371/ journal.pone.0116836.
4. Szałach ŁP, Lisowska KA, Cubała WJ. The influence of antidepressants on the immune system. Arch Immunol Ther Exp (Warsz). 2019;67:143-151.
5. Ahmed F, Gaul C, García-Moncó JC, et al; REPOSE Principal Investigators. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019;20:26. doi: 10.1186/ s10194-019-0976-1.
6. Hess DC, Eldahshan W, Rutkowski E. COVID-19-related stroke. Transl Stroke Res. 2020;11:322-325.
7. American College of Cardiology, American Heart Association, Heart Failure Society of America. HFSA/ ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19, https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsaacc-aha-statement-addresses-concerns-re-using-raasantagonists-in-covid-19; accessed December 2020.
8. Skaria T, Mitchell KJ, Vogel O, et al. Blood pressure normalization-independent cardioprotective effects of endogenous, physical activity-induced αCGRP (α Calcitonin Gene-Related Peptide) in chronically hypertensive mice. Circ Res. 2019;125:1124-1140.
9. Mulder IA, Li M, de Vries T, et al. Anti-migraine calcitonin gene-related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol. 2020;88:771-784.
10. Biohaven Pharmaceuticals. Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant to Treat Lung Inflammation After COVID-19 Infection. 9 April 2020. https://www.biohavenpharma.com/investors/news-events/pressreleases/ 04-09-2020.; accessed December 2020.
11. Han L, Liu Y, Xiong H, et al. CGRP monoclonal antibody for preventive treatment of chronic migraine: an update of meta-analysis. Brain Behav. 2019;9:e01215. doi: 10.1002/brb3.1215.
12. Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. Cephalalgia. 2019;39:445-458.
13. Levin M, Silberstein SD, Gilbert R, et al. Basic considerations for the use of monoclonal antibodies in migraine. Headache. 2018;58:1689-1696.